Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | KDM1A | O60341 | 13/20 | 0.48 |
| ▸ | MAOA | P21397 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3699659 | 0.94 | KMT2A (0.47) | KMT2AKDM1AMAOAMEN1POLB | |
| SCHEMBL3606487 | 0.75 | KMT2A (0.63) | KMT2AKDM1AMAOAMEN1 | |
| SCHEMBL3699658 | 0.75 | KDM1A (0.52) | KMT2AKDM1AMAOAMEN1POLB | |
| SCHEMBL3620828 | 0.70 | KMT2A (0.71) | KMT2AKDM1AMAOAMEN1POLB | |
| Hydrochloric Acid SCHEMBL3620116 | 0.68 | KMT2A (0.59) | KMT2AKDM1AMAOAMEN1 | |
| SCHEMBL3610490 | 0.65 | KMT2A (0.73) | KMT2AKDM1AMAOAMEN1POLB | |
| SCHEMBL3620152 | 0.65 | KMT2A (1.00) | KMT2AMEN1POLB | |
| SCHEMBL3613532 | 0.64 | CTPS1 (0.64) | KMT2AKDM1AMEN1 | |
| SCHEMBL5911665 | 0.64 | KDM1A (0.68) | KMT2AKDM1AMAOAMEN1POLB | |
| SCHEMBL3622331 | 0.63 | KDM1A (0.58) | KMT2AKDM1AMAOAMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2010-05-06 | — | — | US | disclosed |
| US-7618961-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2009-11-17 | — | — | US | disclosed |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2004-11-11 | — | — | US | disclosed |
| EP-1283831-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001090090-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | KMT2A 3300/4885KDM1A 1361/4885MAOA 346/4885 |
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD3B1 | KMT2A 3769/4885KDM1A 1569/4885MAOA 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.